Table 1.

Cytokine concentrations in PHA-stimulated whole blood cultures of healthy controls (HC), patients with Hashimoto thyroiditis (HT patients), patients with papillary thyroid cancer (PTC patients) and patients with papillary thyroid cancer and associated Hashimoto thyroiditis (PTC + HT patients)

Cytokine	HC (n = 12) x ± SD	HT patients (n = 12) x ± SD	PTC patients (n = 12) x ± SD	PTC + HT patients (n = 4) x ± SD
IL-13	144 ± 171	301 ± 137	609 ± 321d,g	4212 ± 3224i
IL-4	91.6 ± 108	85.9 ± 53.7	181 ± 94.6h	404 ± 221j
IL-5	282 ± 314	440 ± 267	857 ± 613e	1906 ± 1015
IL-9	11.9 ± 20.7	40 ± 24.9	47.7 ± 23.1f	199 ± 167k
IFN-γ	7284 ± 6699	14647 ± 3516a	9916 ± 3699	14521 ± 718l
IL-6	1355 ± 1658	4968 ± 3348b	1897 ± 1651	6038 ± 2288m
IL-17A	1521 ± 1393	3487 ± 2793	2965 ± 1652	3673 ± 458
IL-10	203 ± 198	739 ± 358c	547 ± 752	671 ± 516

^a significant difference between HT patients and HC, p = 0.030

^b significant difference between HT patients and HC, p = 0.017

^c significant difference between HT patients and HC, p = 0.005

^d significant difference between PTC patients and HC, p = 0.005

^e significant difference between PTC patients and HC, p = 0.047

^f significant difference between PTC patients and HC, p = 0.010

^g significant difference between PTC patients and HT patients, p = 0.038

^h significant difference between PTC patients and HT patients, p = 0.040

ⁱ significant difference between PTC + HT patients and PTC patients, p = 0.033

^j significant difference between PTC + HT patients and PTC patients, p = 0.047

^k significant difference between PTC + HT patients and PTC patients, p = 0.017

^l significant difference between PTC + HT patients and PTC patients, p = 0.016

^m significant difference between PTC + HT patients and PTC patients, p = 0.011